Trials / Completed
CompletedNCT00442546
Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement
A Multicenter, Double-Blind Randomized, Placebo-Controlled Study Of The Efficacy And Safety Of Pregabalin In The Treatment Of Subjects With Post-Operative Pain Following Total Knee Arthroplasty (TKA)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Pregabalin added to the standard of care with dosing starting preoperatively and continuing for up to 6 weeks post surgery will decrease the intensity of post-operative pain following total knee replacement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pregabalin | 150 milligram (mg)/ day (double blind) |
| DRUG | pregabalin | 300 mg/day (double blind) |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2007-03-02
- Last updated
- 2021-01-22
- Results posted
- 2010-08-18
Locations
27 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00442546. Inclusion in this directory is not an endorsement.